OptimizeRx’s (OPRX) Sector Perform Rating Reaffirmed at Royal Bank of Canada

OptimizeRx (NASDAQ:OPRX)‘s stock had its “sector perform” rating reissued by Royal Bank of Canada in a research note issued to investors on Wednesday, MarketBeat reports. They presently have a $6.00 price objective on the stock, down from their prior price objective of $7.00. Royal Bank of Canada’s price objective points to a potential upside of 10.91% from the stock’s current price.

OPRX has been the topic of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. Roth Mkm reiterated a “buy” rating and issued a $16.00 price target (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Barclays decreased their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. Finally, Stephens started coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Price Performance

Shares of OPRX opened at $5.41 on Wednesday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock’s 50 day moving average is $5.16 and its two-hundred day moving average is $7.25. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The firm has a market capitalization of $99.66 million, a PE ratio of -4.07 and a beta of 1.36.

Insider Buying and Selling at OptimizeRx

In related news, CEO William J. Febbo purchased 20,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the transaction, the chief executive officer now owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Trading of OptimizeRx

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares in the last quarter. Quest Partners LLC raised its position in shares of OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares during the last quarter. Connors Investor Services Inc. lifted its stake in shares of OptimizeRx by 15.1% during the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after buying an additional 2,500 shares during the period. Barclays PLC boosted its position in OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after acquiring an additional 21,060 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in OptimizeRx in the 2nd quarter valued at $282,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.